----item----
version: 1
id: {22C80A2C-A3A8-433D-ADEE-C51823E00323}
database: master
path: /sitecore/content/ScripIntelligence/Home/Articles/2015/10/02/PharmAsia News Business Bulletin
parent: {649A1F5F-680B-4755-ABE7-6BF2F8862CDD}
name: PharmAsia News Business Bulletin
master: {00000000-0000-0000-0000-000000000000}
template: {11380B5D-3531-4570-B213-EFC5312266E4}
templatekey: Article

----version----
language: en
version: 1
revision: a4a2fef3-282e-4d82-90e9-87d42da0c4be

----field----
field: {2D750EFF-9058-4ABF-A7FF-57FFE5DA1E3C}
name: Title
key: title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {F1D1DC93-63DF-4AFA-B60F-B3A3E9D36675}
name: Sub Title
key: sub title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {446A339B-E1D9-4DE1-8B5E-DB7942EF1723}
name: Body
key: body
content-length: 3441

<p>A new regular roundup of commercial stories appearing in Scrip&rsquo;s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p><p>Full stories can be accessed by clicking on the story title (subscription required).</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/2/genovate-aims-for-global-insulin-position-under-$1bn-project" target="_new">Genovate Aims For Global Insulin Position Under $1bn Project</a></p><p>Genovate has begun construction of its first manufacturing facility for insulins as part of a total investment of $1bn and with the ambition to become China&rsquo;s first, and the world's fourth largest, manufacturer of insulin using efficient and ecologically friendly production technology.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/10/1/govt-support-bolsters-pharmicells-stem-cell-therapy-plans" target="_new">Govt Support Bolsters Pharmicell&rsquo;s Stem Cell Therapy Plans</a></p><p>Pharmicell is to kick off the development of a stem cell-based therapy for chronic kidney disease and a gene therapy for liver cancer with support from the South Korean government, which is nurturing the development of both sectors as part of a national strategic plan.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/30/law-change-would-help-kolon-as-it-progresses-pipeline" target="_new">Law Change Would Help Kolon As It Progresses Pipeline</a></p><p>Kolon life Science expects South Korea&rsquo;s government to ease gene therapy rules to help the company launch its osteoarthritis drug in the domestic market, and is looking to complete licensing talks with potential global partners before the product's launch, the venture said at a recent investors&rsquo; meeting.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/29/viekirax-approval-set-to-rattle-japan-hep-c-market" target="_new">Viekirax Approval Set To Rattle Japan Hep C Market</a></p><p>AbbVie's all-oral, interferon- and ribavirin-free combination therapy for hepatitis C, Viekirax, has been approved in Japan, setting the stage for intensified competition in what is a large market.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/29/hanmi-lg-highlight-diabetes-pipeline-progress-at-easd" target="_new">Hanmi, LG Highlight Diabetes Pipeline Progress At EASD</a></p><p>South Korea&rsquo;s Hanmi Pharmaceutical and LG Life Sciences presented progress across their diabetes pipelines at the recent annual EASD meeting, with both firms unveiling promising results from a range of studies.</p><p><p><a href="https://www.pharmamedtechbi.com/publications/pharmasia-news/2015/9/28/viralytics-looks-to-combos-to-ride-immunooncology-wave" target="_new">Viralytics Looks To Combos To Ride Immuno-Oncology Wave</a></p><p>Australian oncology venture Viralytics is on something of a roll, announcing additional positive Phase II data for its lead drug Cavatak and progress with new plans to assess the oncolytic virus in combination with immune checkpoint inhibitors following promising early results.</p><p><p><a href="http://C:\Users\haydocki\AppData\Local\Microsoft\Windows\Temporary Internet Files\Content.IE5\RXQFB8U9\www.pharmasianews.com" target="_new">www.pharmasianews.com</a></p><p>
----field----
field: {5BA0578F-65B7-4C22-8233-1603D698D8A4}
name: Summary
key: summary
content-length: 235

<p>A new regular roundup of commercial stories appearing in Scrip&rsquo;s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace.</p>
----field----
field: {8F4EE718-6FA0-42A5-85C4-6C8FE8B1FCD4}
name: Navigation Title
key: navigation title
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {7C4FC796-1311-4DAA-81AC-85EAA2C1C108}
name: Actual Publish Date
key: actual publish date
content-length: 15

20151002T182314
----field----
field: {BDF7C8E1-869E-49FF-B9F5-854B3081A45D}
name: Created Date
key: created date
content-length: 15

20151002T182314
----field----
field: {C926A72A-39DA-446D-B78C-2A650F820A73}
name: Modified Date
key: modified date
content-length: 15

20151002T182314
----field----
field: {1616FE67-7278-4169-948E-C29B00EC8781}
name: Article Number
key: article number
content-length: 8

SC029941
----field----
field: {31603F25-6D9C-4954-BCDE-342E1E184A30}
name: Meta Title Override
key: meta title override
content-length: 32

PharmAsia News Business Bulletin
----field----
field: {5AD65E47-7554-4CE5-87B0-7FB65051C05A}
name: Authors
key: authors
content-length: 38

{DB39CCA6-EB88-422C-8247-AB4AD01491E2}
----field----
field: {0F6C8F42-01DC-4E05-B63E-AA25D8AA0E09}
name: Legacy Publication
key: legacy publication
content-length: 38

{0F9CCE10-91C1-4F31-832A-266F482A5DAF}
----field----
field: {5795FF15-0942-41FF-8A77-3B73185F5E1B}
name: Escenic ID
key: escenic id
content-length: 6

360705
----field----
field: {25BED78C-4957-4165-998A-CA1B52F67497}
name: __Created
key: __created
content-length: 16

20160209T042458Z
----field----
field: {5DD74568-4D4B-44C1-B513-0AF5F4CDA34F}
name: __Created by
key: __created by
content-length: 18

sitecore\Anonymous
----field----
field: {8CDC337E-A112-42FB-BBB4-4143751E123F}
name: __Revision
key: __revision
content-length: 36

a4a2fef3-282e-4d82-90e9-87d42da0c4be
----field----
field: {D9CF14B1-FA16-4BA6-9288-E8A174D4D522}
name: __Updated
key: __updated
content-length: 16

20160209T042458Z
----field----
field: {BADD9CF9-53E0-4D0C-BCC0-2D784C282F6A}
name: __Updated by
key: __updated by
content-length: 18

sitecore\Anonymous
